JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuel, M. A.
Right arrow Articles by Diamond, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuel, M. A.
Right arrow Articles by Diamond, M. S.
Journal of Virology, July 2006, p. 7009-7019, Vol. 80, No. 14
0022-538X/06/$08.00+0     doi:10.1128/JVI.00489-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

PKR and RNase L Contribute to Protection against Lethal West Nile Virus Infection by Controlling Early Viral Spread in the Periphery and Replication in Neurons

Melanie A. Samuel,1 Kevin Whitby ,2,{dagger} Brian C. Keller,3 Anantha Marri,2 Winfried Barchet,4 Bryan R. G. Williams,5,{ddagger} Robert H. Silverman,5 Michael Gale Jr.,3 and Michael S. Diamond1,2,4*

Departments of Molecular Microbiology,1 Medicine,2 Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri 63110,4 Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9048,3 Department of Cancer Biology/NB40, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 441955

Received 8 March 2006/ Accepted 17 April 2006


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
West Nile virus (WNV) is a neurotropic, mosquito-borne flavivirus that can cause lethal meningoencephalitis. Type I interferon (IFN) plays a critical role in controlling WNV replication, spread, and tropism. In this study, we begin to examine the effector mechanisms by which type I IFN inhibits WNV infection. Mice lacking both the interferon-induced, double-stranded-RNA-activated protein kinase (PKR) and the endoribonuclease of the 2',5'-oligoadenylate synthetase-RNase L system (PKR–/– x RL–/–) were highly susceptible to subcutaneous WNV infection, with a 90% mortality rate compared to the 30% mortality rate observed in congenic wild-type mice. PKR–/– x RL–/– mice had increased viral loads in their draining lymph nodes, sera, and spleens, which led to early viral entry into the central nervous system (CNS) and higher viral burden in neuronal tissues. Although mice lacking RNase L showed a higher CNS viral burden and an increased mortality, they were less susceptible than the PKR–/– x RL–/– mice; thus, we also infer an antiviral role for PKR in the control of WNV infection. Notably, a deficiency in both PKR and RNase L resulted in a decreased ability of type I IFN to inhibit WNV in primary macrophages and cortical neurons. In contrast, the peripheral neurons of the superior cervical ganglia of PKR–/– x RL–/– mice showed no deficiency in the IFN-mediated inhibition of WNV. Our data suggest that PKR and RNase L contribute to IFN-mediated protection in a cell-restricted manner and control WNV infection in peripheral tissues and some neuronal subtypes.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
West Nile virus (WNV) is a neurotropic flavivirus that, in nature, cycles through mosquitoes and birds and can infect humans and other mammals. Humans develop a febrile illness that can progress to neurological disease, including encephalitis, meningitis, and poliomyelitis (3, 8, 43, 44, 65). Initial viral replication is thought to occur in skin Langerhans' dendritic cells, followed by seeding of draining lymph nodes and viremia (6, 33). WNV crosses into the central nervous system (CNS) through an undefined mechanism that may involve tumor necrosis factor-{alpha}-mediated changes in blood-brain barrier permeability (73). Upon CNS entry, WNV infects and injures several different neuronal cell populations, including those in the cerebral cortex, brain stem, hippocampus, and spinal cord (14, 19, 21, 55, 68, 76).

In humans, increased disease susceptibility is correlated with depressed immunity and increased age (11, 29, 32, 39). The immunologic basis for resistance to flaviviruses has begun to be elucidated using rodent models and human genetic analysis. Humoral immunity and cytotoxic-T-lymphocyte responses are important in controlling WNV infection and spread, as both B-cell- and CD8+ T-cell-deficient mice showed significantly increased viral burden and lethality (14, 68a, 73a). In humans, a defective allele for the chemokine receptor CCR5 has been linked to an increased risk for symptomatic WNV infection (26); in mice, a deficiency in CCR5 is associated with decreased leukocyte trafficking to the CNS and a higher viral burden (25). Less is known regarding the mechanisms by which innate immunity controls flavivirus infection. Recent studies suggest that host cells respond to WNV through retinoic acid-inducible gene I (RIG-I)- and interferon regulatory factor 3 (IRF-3)-dependent pathways, resulting in the production of several interferon (IFN)-stimulated genes and the inhibition of cell-to-cell spread (22, 23). Several flavivirus nonstructural proteins antagonize this antiviral response by impairing IFN gene transcription and type I IFN signaling (30, 46-48, 54). Although flaviviruses can counter IFN-induced responses within infected cells, IFN is still essential for limiting viral dissemination in vivo (49, 62, 67). After WNV infection, type I IFN is produced in both the serum and the brain, and a deficiency in the IFN-{alpha}/ß receptor (IFN-{alpha}/ßR–/–) in mice resulted in uncontrolled viral replication, swift spread to the CNS, altered viral tropism, and rapid lethality (62). Although type I IFN is critical for the defense against flavivirus infections, the specific downstream antiviral effector mechanisms remain largely uncharacterized.

Type I IFNs induce an antiviral state within cells through the upregulation and activation of an array of antiviral effector molecules (reviewed in reference 57). Among these, the double-stranded RNA (dsRNA)-dependent protein kinase (PKR) and 2',5'-oligoadenylate synthetase (OAS) proteins act as key mediators of intracellular resistance to several viruses (70, 75). PKR undergoes autophosphorylation after binding dsRNA and/or the PKR-activating (PACT) protein. The {alpha} subunit of eukaryotic translation initiation factor 2 (eIF2-{alpha}) is a central target for phosphorylation by activated PKR, resulting in a block of protein synthesis (52). OAS enzymes are activated by dsRNA to synthesize 2',5'-linked oligoadenylates (36), which then bind and activate RNase L, an endoribonuclease that cleaves viral RNA and mRNA, leading to a decrease in protein synthesis and viral replication (69). In vitro, disparate cell populations have shown distinct dependencies on PKR and RNase L to modulate the replication of different viruses. Increased basal replication and persistence by the alphavirus Sindbis were observed in RNase L-deficient mouse embryonic fibroblasts (MEFs) and in bone marrow-derived dendritic cells (BM-DCs) of PKR–/– x RL–/– mice (60, 63). Despite this increased viral production, the IFN responsiveness of these cells remained largely intact in the absence of PKR and RNase L (59, 60). In contrast, PKR-deficient MEFs showed decreased type I IFN-mediated protection from vesicular stomatitis virus (VSV) infection (71), and PKR partially mediated the antiviral effects of IFN-ß against herpes simplex virus (HSV) in trigeminal ganglion neurons (2). Members of the Flaviviridae family of RNA viruses also have exhibited varied sensitivities to PKR and RNase L in vitro. Although RNase L-deficient MEFs supported increased WNV replication, this phenotype appeared independent of IFN (64). Consistent with this, the absence of PKR and RNase L did not alter the IFN-ß-mediated inhibition of dengue virus (13). In contrast, both effector molecules were implicated in the control of hepatitis C virus polyprotein production (27).

Despite the accumulation of in vitro data, the roles of PKR and RNase L have not been directly tested in vivo for any Flaviviridae family member. These proteins do, however, partially mediate antiviral resistance in mice for some viruses. Mice lacking PKR showed increased lethality following VSV infection (16, 71) and more severe ocular HSV disease (7). Mice deficient in PKR and/or RNase L showed increased mortality following coxsackievirus infection (20). In contrast, PKR–/– x RL–/– mice showed no increase in morbidity or mortality following alphavirus Sindbis virus infection, although increased viral loads in draining lymph nodes were observed (60). Thus, the ability of PKR and RNase L to mediate IFN-induced protection appears to vary across families of DNA and RNA viruses. Herein, we directly evaluate the roles of PKR and RNase L in controlling WNV replication and dissemination in mice and compare these to their antiviral effects in primary cells.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Viruses. The WNV strain (3000.0259) was isolated in New York in 2000 after the inoculation of a mosquito homogenate onto Vero cells as previously described (18) and passaged once in C6/36 cells to generate a stock virus that was used in all experiments.

Mouse experiments and quantitation of viral burden. C57BL/6 wild-type inbred mice were obtained commercially (Jackson Laboratories, Bar Harbor, ME). RL–/– (81) and PKR–/– x RL–/– mice (78, 82) that were backcrossed 10 generations into the C57BL/6 background were genotyped and bred in the animal facility of Washington University School of Medicine, and experiments were performed in accordance with Washington University's animal studies guidelines. Eight- to ten-week-old mice were used for all in vivo studies. Peripheral infection was performed by footpad inoculation of 102 PFU of virus diluted in Hanks balanced salt solution (HBSS) with 1% heat-inactivated fetal bovine serum (FBS). Intracranial (IC) inoculation was performed using a tuberculin syringe with 101 PFU of virus diluted in 10 µl HBSS with 1% FBS. To examine the kinetics of viral spread and replication, mice were infected with 102 PFU of virus by footpad inoculation and euthanized on days 1, 2, 3, 4, 6, 8, and 10 after infection. Blood was collected by phlebotomy from the axillary vein, and sera were recovered, aliquoted, and stored at –80°C. To determine viral titers, mice were perfused with 10 to 20 ml of phosphate-buffered saline and organs were removed, weighed, and homogenized. Plaque assays were performed as previously described using BHK21 cells (14). Viral RNA was prepared from aliquots of sera with a Qia-Amp RNA recovery kit and from inguinal lymph nodes with an RNEasy kit according to the manufacturer's instructions (QIAGEN, Valencia, CA). WNV RNA was quantitated by real-time fluorogenic reverse transcription (RT)-PCR as described previously (14) using the following primers and probe to the E gene of WNV: the forward primer 5'-TCAGCGATCTCTCCACCAAAG-3', the reverse primer 5'-GGGTCAGCACGTTTGTCATTG-3', and the probe 5'-FAM (6-carboxyfluorescein)-TGCCCGACCATGGGAGAAGCTC-3'-TAMRA (6-carboxytetramethylrhodamine) (42). To normalize lymph node RNA samples, fluorogenic RT-PCR was performed in parallel on 18S rRNA (Applied Biosystems, Foster City, CA).

IFN levels in serum. The level of biologically active type I IFN in serum was determined using an encephalomyocarditis virus (EMCV) bioassay of L929 cells as previously described (4). Briefly, 8- to 9-week-old C57BL/6 and congenic PKR–/– x RL–/– mice were infected by footpad inoculation with 102 PFU, and serum samples were harvested on days 1, 2, 3, 4, and 5 after infection, as described above. Serial dilutions of sera in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS were applied in duplicate to monolayers of L929 cells (1.8 x 104 cells/well) in 96-well plates. Following incubation for 14 h at 37°C, cells were infected with EMCV diluted in DMEM containing 2% FBS at a multiplicity of infection (MOI) of 7. Cells were inspected for cytopathic effect, and 7 hours postinfection, IFN-mediated protection was assayed using a CellTiter 96 aqueous cell proliferation assay as per the manufacturer's instructions (Promega Corporation, Madison, WI).

Strand-specific real-time RT-PCR. Strand-specific real-time RT-PCR was performed as previously described (62). Briefly, spleens were dissected from WNV-infected wild-type C57BL/6 and congenic RL–/– and PKR–/– x RL–/– mice on day 4, and single-cell suspensions were generated following treatment with type IV collagenase for 30 min at 37°C (Worthington Biochemical, Lakewood, NJ). Cells were washed with DMEM, and CD11b+, CD11c+, and CD19+ cells were isolated by positive selection using antibody-conjugated magnetic beads as per the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). Cell purity was assessed by flow cytometry using fluorescent conjugated antibodies against CD11b, CD11c, and B220 antigens (BD Pharmingen, San Diego, CA). RNA was extracted from purified cells using an RNEasy kit as per the manufacturer's instructions (QIAGEN). Strand-specific reverse transcription was performed for 30 min at 55°C using T7-tagged primers as previously described (62). Following a 10-min incubation at 95°C to inactivate the reverse transcriptase, 5 pmol of the probe (5'-FAM-CAACCTCACCTACAGGGCGGACTTCAAG-TAMRA-3') and 20 pmol each of primers T7 and E1160F were added to positive-strand reaction mixtures and primers T7 and E1229R were added to negative-strand reaction mixtures. The thermal cycling reaction was then allowed to proceed (40 cycles of 95°C for 15 s and then 60°C for 1 min). To normalize the samples, the amount of 18S rRNA (Applied Biosystems) in each sample was determined by fluorogenic RT-PCR, performed in parallel assays.

Primary-cell cultures. Bone marrow-derived macrophages (BM-M{phi}) and dendritic cells (BM-DCs) were generated as described previously (9, 72) with the following modifications. Briefly, bone marrow cells derived from C57BL/6 wild-type and congenic PKR–/– x RL–/– and RL–/– mice were cultured in 12-well plates at a density of 1.5 x 105 cells per well. BM-M{phi} were grown in DMEM supplemented with 10% defined fetal calf serum (HyClone), 40 ng/ml macrophage colony-stimulating factor (M-CSF) (PeproTech, Inc., Rocky Hill, NJ), sodium pyruvate, penicillin-streptomycin, and glutamine for 6 days. BM-DCs were cultured in RPMI medium supplemented with 10% defined fetal calf serum (HyClone), 20 ng/ml granulocyte-macrophage colony-stimulating factor, 20 ng/ml interleukin 4 (PeproTech, Inc., Rocky Hill, NJ), sodium pyruvate, kanamycin sulfate, nonessential amino acids, and glutamine for 6 days. Beginning on day 7, BM-M{phi} and BM-DCs were maintained in 20 ng/ml M-CSF or 10 ng/ml granulocyte-M-CSF and 10 ng/ml interleukin 4, respectively. All bone marrow-derived cell experiments were performed on cells cultured for 7 to 8 days. Purity was determined by flow cytometry following staining with an anti-F4/80 antibody (BM-M{phi}) (Serotec, Inc., Raleigh, NC) or an anti-CD11c+ antibody (BM-DCs) (BD Pharmingen, San Diego, CA). Primary cortical neurons were prepared from day 15 C57BL/6 and congenic RL–/– and PKR–/– x RL–/– mouse embryos essentially as previously described (38, 80). Cortical neuron experiments were performed using neurons that were cultured for 3 to 4 days. Primary sympathetic neuronal cultures were generated from superior cervical ganglia (SCG) of 1-day-old mice as reported previously (17). The purity of SCG cultures was determined via staining with anti-NeuN and anti-GFAP antibodies (~98 to 99%) (58). All SCG neuron experiments were performed on neurons cultured 6 to 7 days prior to treatment or infection.

IFN treatment of primary cells and virus infection. To assay IFN inhibition of WNV replication, BM-M{phi}, BM-DCs, and cortical and SCG neurons were treated with 100 IU/ml (neurons) or 1,000 IU/ml (bone marrow-derived cells) of mouse IFN-{alpha}, IFN-ß, or IFN-{gamma} (PBL Laboratories, Madison, WI) 24 h prior to infection or at the time of infection. Cortical neurons and BM-M{phi}s were infected at an MOI of 0.1 and SCG neurons at an MOI of 10 for 1 h, followed by extensive washing to remove free virus. Supernatants were harvested at 24 h postinfection. To determine WNV growth kinetics in BM-M{phi} and BM-DCs, cells were infected at an MOI of 0.01 for 1 h and washed extensively, and supernatants were harvested at 6, 24, and 48 h postinfection. The production of infectious virus was measured by a plaque assay on Vero cells as described previously (14).

Western blotting. Cortical neurons were lysed in radioimmunoprecipitation assay buffer (10 mM Tris, 150 mM NaCl, 0.02% sodium azide, 1% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, pH 7.4) with protease inhibitors (Sigma). Samples (30 µg) were resolved on 10% sodium dodecyl sulfate-polyacrylamide gels. Following transfer, membranes were blocked with 5% nonfat dried milk overnight at 4°C. Membranes were probed with the following panel of monoclonal or polyclonal antibodies: phosphorylated anti-PKR and anti-eIF2{alpha} (Cell Signaling), anti-eIF2{alpha} (24), anti-PKR and anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (Santa Cruz Biotechnology), anti-mouse IRF-3 (Zymed Laboratories), anti-mouse interferon-stimulated gene 56 (ISG56) and anti-mouse ISG54 (kind gifts from Ganes Sen), and anti-WNV (Centers for Disease Control and Prevention). Blots were subsequently incubated with peroxidase-conjugated secondary antibodies (Jackson Immunoresearch) and visualized using ECL-Plus immunoblotting reagents (Amersham Biosciences).

Statistical analysis. For in vitro experiments, an unpaired t test was used to determine significant differences. For viral burden analysis, differences in log titers were analyzed by the Mann-Whitney test. Kaplan-Meier survival curves were analyzed by the log rank test. All data were analyzed using Prism software (GraphPad, San Diego, CA).


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Effect of RNase L and PKR on WNV pathogenesis in mice. Mice lacking the type I IFN receptor show extreme susceptibility to peripheral WNV infection, with 100% mortality by day 5 postinfection (62). Type I IFN restricts intracellular viral replication by inducing and activating an array of antiviral effector molecules. To investigate the mechanisms by which type I IFN controls WNV infection, we evaluated survival rates of mice lacking two key IFN-induced effector proteins, PKR and RNase L. After their footpads were inoculated with 102 PFU of WNV, mice lacking both PKR and RNase L (PKR–/– x RL–/–) showed acute clinical symptoms by day 8 to 9 postinfection, including a hunchback posture, weight loss, fur ruffling, and reduced activity. Although wild-type mice that progressed to death showed similar clinical signs, the rate and severity of clinical manifestations were lower. PKR–/– x RL–/– mice were more vulnerable to lethal WNV infection, with a 10% survival rate compared to 70% for wild-type mice (P < 0.0001) (Fig. 1A). RNase L-deficient mice (RL–/–) also showed an increased susceptibility to WNV infection (51% survival; P = 0.03), although they were less vulnerable than mice lacking both PKR and RNase L. These results suggest that the activities of PKR and RNase L play nonredundant, important roles in protecting mice from fatal WNV infection.


Figure 1
View larger version (22K):
[in this window]
[in a new window]
  		FIG. 1. Survival and virologic analysis for wild-type (WT), RL–/–, PKR–/– x RL–/–, and IFN-{alpha}/ßR–/– C57BL/6 mice. (A) Eight- to 10-week-old mice were inoculated with 102 PFU of WNV by footpad injection and followed for mortality for 25 days. The number of mice in these experiments was as follows: 50 wild-type, 29 RL–/–, 18 PKR–/– x RL–/–, and 11 IFN-{alpha}/ßR–/– mice. Survival differences between wild-type and all immunodeficient mice were statistically significant (P ≤ 0.03). (B and C) Viral burdens in the CNS after WNV infection. Viral loads in the brain (B) and spinal cord (C) were determined from samples harvested on days 2, 4, 6, 8, and 10 using a viral plaque assay on BHK21 cells. Data are shown as the PFU per gram of tissue for 5 to 17 mice per time point. For all viral load data, the solid line represents the mean PFU per gram at the indicated time point, and the dotted line represents the limit of sensitivity of the assay. Asterisks indicate values that are statistically significant (P < 0.05) compared to those for wild-type mice.

 
PKR and RNase L are required for controlling WNV infection in mice. Because PKR and RNase L function to restrict intracellular viral replication (5, 28, 37, 45), we predicted that the enhanced lethality of mice lacking these effectors would correlate with increased viral burdens. To evaluate this, RL–/–, PKR–/– x RL–/–, and wild-type mice were infected with 102 PFU, and CNS tissues were harvested on days 2, 4, 6, 8, and 10 after infection. Though dissemination rates and viral loads in the brains of RL–/– mice were largely indistinguishable from those in wild-type mice, mice that lacked both PKR and RNase L showed earlier WNV entry into the CNS and enhanced infection (Fig. 1B). At day 4, infectious WNV was present in the brains of 50% (four of eight) of the PKR–/– x RL–/– mice compared to 0% (zero of eight) of the wild-type mice. PKR–/– x RL–/– mice continued to show significantly increased viral burdens in their brains on day 6 after infection (105.0 PFU/g versus 103.9 PFU/g; P < 0.05). By day 10, PKR–/– x RL–/– mice averaged 10-fold-higher viral titers than wild-type mice, corresponding with increased symptoms and death (P = 0.03). In contrast, the kinetics and magnitude of the viral burdens in the spinal cords of RL–/– and PKR–/– x RL–/– mice were not statistically different from those of the wild-type mice, although viral burdens in the PKR–/– x RL–/– mice trended toward higher levels after day 8 (Fig. 1C).

PKR and RNase L control early viral replication in peripheral lymphoid tissues. WNV is believed to replicate in skin dendritic cells, resulting in seeding of the draining lymph node and viremia (6, 33). Type I IFN is essential for limiting WNV replication soon after infection, as mice lacking the IFN-{alpha}/ß receptor demonstrated high levels of infectious virus in their sera and spleens at early time points (62). Because we observed early WNV entry into the brains of PKR–/– x RL–/– mice, we speculated that PKR and RNase L modulated WNV replication in peripheral tissues. To examine this, viral levels in the lymph node, spleen, and serum were determined during early stages of infection.

(i) Lymph node. Viral RNA levels were assayed in the draining lymph node that was ipsilateral to the infection site by a quantitative fluorogenic RT-PCR assay. Low levels of viral RNA were detected in lymph nodes in all groups 1 day after infection. However, at day 2, both RL–/– and PKR–/– x RL–/– mice averaged fourfold-higher levels of WNV RNA than wild-type mice (P = 0.04) (Fig. 2A). These data suggest that PKR and RNase L limit viral replication in the lymph node at early time points.


Figure 2
View larger version (23K):
[in this window]
[in a new window]
  		FIG. 2. PKR–/– x RL–/– mice show increased viral replication in the periphery. (A to C) Viral burdens in the lymph nodes, sera, and spleens of wild-type (WT), RL–/–, and PKR–/– x RL–/– mice following footpad infection with 102 PFU of WNV. (A) Levels of viral RNA were measured from inguinal lymph nodes ipsilateral to the site of infection by quantitative RT-PCR. Data are shown as the genomic equivalents of WNV RNA per ng of 18S rRNA. (B) Viral RNA levels in sera were analyzed via quantitative RT-PCR. Data shown are genomic equivalents of WNV RNA per milliliter of serum. (C) WNV burden in the spleen was measured by plaque assay using samples harvested on the indicated days and is expressed as PFU per gram of tissue. The dotted line represents the limit of sensitivity of the assay. (D) Type I IFN concentrations were determined from sera collected on days 1 to 5 after infection by using an EMCV bioassay in L929 cells. Data reflect the averages from serum samples harvested from three to five mice per time point and are shown as units of IFN/ml of serum. (E) WNV-specific IgM levels were determined from sera collected on day 4 postinfection by enzyme-linked immunosorbent assay against purified recombinant WNV E protein. Data represent the averages from samples harvested from eight mice per group and are expressed as units of optical density after subtraction of the background. Error bars indicate the standard deviations, and asterisks indicate values that are statistically significant (P < 0.05) compared to those for wild-type mice in all panels.

 
(ii) Viremia. WNV RNA was detected in the sera of wild-type, RL–/–, and PKR–/– x RL–/– mice beginning on day 1 after infection by quantitative fluorogenic RT-PCR and peaked in all groups on day 3 after infection. In wild-type mice, WNV RNA levels subsequently decreased on day 4 and largely approached the limit of detection by day 6. However, PKR–/– x RL–/– mice showed a somewhat delayed clearance of viral RNA from their sera, with statistically higher levels of viral RNA on day 4 than in wild-type mice (102.5 viral copies/ml versus 101.4 viral copies/ml, respectively; P = 0.003) (Fig. 2B). Thus, higher levels of circulating WNV were detected in PKR- and RNase L-deficient mice, and this finding correlated kinetically with the observed earlier entry of WNV into the CNS.

(iii) Spleen. Infectious WNV was detected by plaque assay at equivalent levels in the spleens of RL–/–, PKR–/– x RL–/–, and wild-type mice beginning on day 3 after infection. By day 4, however, only 66% (six of nine) of the wild-type mice had viral loads above the limit of detection, whereas 88% (seven of eight) of the RL–/– and 100% (eight of eight) of the PKR–/– x RL–/– mice showed splenic infection. Consistent with this, PKR–/– x RL–/– mice had significantly higher viral burdens at day 4 than wild-type mice (104.7 PFU/g versus 103.6 PFU/g, respectively; P < 0.05) (Fig. 2C). Despite the increased level of WNV in the spleens of PKR–/– x RL–/– mice, virus was cleared with similar kinetics in all groups of mice, and infectious virus was no longer detectable by day 8 after infection.

(iv) Type I IFN production. In addition to other molecules (e.g., TLR3 and RIG-I [1, 79]), PKR acts as an intracellular sensor for dsRNA and has been linked to type I IFN production in some cell types (10, 31, 41, 50). To determine if an altered production of type I IFN in PKR–/– x RL–/– mice contributed to the observed increase in peripheral viral burden, we compared IFN levels in sera on days 1 to 5 after infection using an EMCV bioassay of L929 cells. Notably, no significant differences in the serum levels of type I IFN-mediated protection were detected between wild-type and PKR–/– x RL–/– mice (P ≥ 0.1) (Fig. 2D).

(v) WNV-specific IgM production. The induction of specific, neutralizing immunoglobulin M (IgM) early in the course of WNV infection has been shown to limit viremia and the spread to CNS tissues (15). Since one in vitro study suggested that PKR may regulate the transcriptional activation of immunoglobulin {kappa} (light chain) (40), we evaluated whether PKR–/– x RL–/– mice had altered levels of WNV-specific IgM early in infection. Sera were harvested on day 4 after infection and analyzed for WNV-specific IgM levels. This day was chosen because differences in IgM response at day 4 correlate with changes in clinical phenotype (15). No significant difference (P = 0.6) was found in the levels of production of WNV-specific IgM between wild-type and PKR–/– x RL–/– mice, suggesting that the increased levels of WNV observed in peripheral compartments was not due to the altered production of WNV-specific IgM (Fig. 2E).

PKR and RNase L modulate cellular infection in the spleen. Type I IFN modulates the tropism of WNV at a cellular level, as mice lacking the type I IFN receptor showed higher spleen viral burdens that reflected increased infection in bone marrow-derived cell populations (62). Since PKR–/– x RL–/– mice also showed increased infection in the spleen, we tested whether PKR and RNase L altered viral infection in specific cell populations. Spleens were harvested from wild-type, PKR–/– x RL–/–, and RL–/– mice on day 4 after infection, and CD11c+, CD11b+, and CD19+ cell populations were isolated by positive selection with antibody-coated magnetic beads. Following RNA isolation, strand-specific, quantitative fluorogenic RT-PCR was performed to assess the levels of WNV positive- and negative-sense RNA. Increased levels of WNV positive-strand RNA were detected in CD11b+, CD11c+, and CD19+ cells isolated from PKR–/– x RL–/– mice (295-, 127-, and 82-fold increases, respectively, relative to levels in wild-type mice; P < 0.03) (Fig. 3A and B and data not shown). Higher levels of positive-strand RNA were also detected in cell populations of RL–/– mice (50-, 6-, and 43-fold increases in CD11b+, CD11c+, and CD19+ cells, respectively; P < 0.04), although levels were lower than those detected in PKR–/– x RL–/– mice. WNV negative strand, a direct marker of active viral replication, was detected in CD11b+ cells isolated from PKR–/– x RL–/– mice, but the level was below the sensitivity of the assay in other tested cell populations from all groups of mice. These data suggest that the lack of PKR and RNase L directly affects infection by WNV in the spleen and that replication in CD11b+ bone marrow-derived cells is enhanced.


Figure 3
View larger version (35K):
[in this window]
[in a new window]
  		FIG. 3. PKR and RNase L modulate viral infection in bone marrow-derived cells. (A and B) Total RNA from CD11b+ (A) and CD11c+ (B) splenocytes isolated on day 4 postinfection was analyzed for the levels of WNV positive and negative strands with strand-specific real-time RT-PCR. Data are expressed as the amounts of positive- and negative-strand RNA relative to 18S rRNA levels. Average values are from four to eight mice per group. BM-M{phi} (C) and BM-DCs (D) were generated from wild-type, RL–/–, and PKR–/– x RL–/– mice and treated for 24 h with 1,000 IU/ml of mouse IFN-ß or -{gamma} prior to infection with an MOI of 0.1. The production of infectious virus at 24 h postinfection was determined by plaque assay. Average values represent results from quadruplicate samples harvested from three independent experiments. BM-M{phi} (E) and BM-DCs (F) generated from wild-type, RL–/–, and PKR–/– x RL–/– mice were infected at an MOI of 0.01, and viral production was evaluated at the indicated times postinfection by plaque assay. Values are averages of results from quadruplicate samples generated from two independent experiments, and asterisks indicate differences that are statistically significant relative to results for wild-type mice (P < 0.05).

 
To test directly whether PKR and RNase L contribute to IFN-mediated inhibition of WNV replication in myeloid cells, we generated BM-M{phi} and BM-DCs from C57BL/6 wild-type and congenic PKR–/– x RL–/– and RL–/– mice. Pretreatment of wild-type BM-M{phi} and BM-DCs with IFN-ß reduced WNV replication to similar levels (104- to 105-fold inhibition). Small but significant decreases in IFN-ß-mediated inhibition of WNV infection were detected in RL–/– and PKR–/– x RL–/– BM-M{phi}s (three- and sixfold reduction, respectively; P ≤ 0.002) (Fig. 3C). In contrast, the IFN-ß-mediated inhibition of WNV in BM-DCs appeared to be independent of PKR and RNase L (P ≥ 0.1) (Fig. 3D). Moreover, RL–/– and PKR–/– x RL–/– BM-M{phi}s supported WNV replication more efficiently than wild-type BM-M{phi}s at 24 h postinfection (P ≤ 0.002) (Fig. 3E), whereas no significant difference in the levels of viral growth in BM-DCs was observed (Fig. 3F). IFN-{gamma} pretreatment of wild-type BM-M{phi}s and BM-DCs also inhibited WNV replication, although BM-DCs responded less efficiently than BM-M{phi}s to this cytokine (103-fold versus 101-fold inhibition). Additionally, while PKR and RNase L were not required for the IFN-{gamma}-induced restriction of WNV in BM-M{phi}s, a small but significant decrease in IFN-{gamma}-mediated inhibition of WNV was observed in PKR–/– x RL–/– BM-DCs (sixfold reduction; P = 0.0001). Together, these experiments suggest that PKR and RNase L contribute to IFN-induced protection in a subset of bone marrow-derived cells in vivo and in vitro.

PKR and RNase L do not control mortality after IC infection. In addition to controlling the dissemination of WNV, type I IFN plays an independent role in limiting WNV replication in CNS tissues directly (62). To test whether PKR and RNase L mediated this effect, we inoculated wild-type, RL–/–, PKR–/– x RL–/–, and IFN-{alpha}/ßR–/– C57BL/6 mice with 101 PFU WNV via the IC route and monitored their survival. All groups of mice showed rapid and nearly complete mortality following IC infection. Similar to results observed in 129Sv/Ev mice (62), IFN-{alpha}/ßR–/– C57BL/6 mice showed a marked vulnerability, with a mean time to death of 3.1 ± 0.1 days compared to 7.3 ± 1.2 days for wild-type mice (P < 0.0001). In contrast, the survival curves for wild-type, RL–/–, and PKR–/– x RL–/– mice were virtually identical (P > 0.2) (Fig. 4A). These experiments suggest that PKR- and RNase L-independent antiviral effector mechanisms function downstream of type I IFN to control WNV-induced mortality after IC infection.


Figure 4
View larger version (17K):
[in this window]
[in a new window]
  		FIG. 4. Survival and viral burden data for wild-type (WT), RL–/–, PKR–/– x RL–/–, and IFN-{alpha}/ßR–/– C57BL/6 mice after intracranial inoculation with 101 PFU of WNV. (A) Data from two to three independent experiments were used to construct the survival curves, for which 44 wild-type, 31 RL–/–, 22 PKR–/– x RL–/–, and 9 IFN-{alpha}/ ßR–/– mice were used. The mean times to death for wild-type, RL–/–, and PKR–/– x RL–/– mice were not statistically different, whereas the mean time to death for IFN-{alpha}/ßR–/– mice was significantly decreased (P < 0.0001). (B through E) Viral burden in tissues after intracranial WNV infection. Viral loads in brain (B), spinal cord (C), spleen (D), and liver (E) were measured by plaque assay from samples harvested on days 2, 4, and 6 after infection and reflect results for four to eight mice per group. The dotted line represents the limit of sensitivity of the assay, and asterisks indicate values that are statistically significant (P < 0.05) compared to those for wild-type mice.

 
PKR and RNase L control viral replication and spread following IC inoculation. Given the high degree of neurovirulence of the lineage I New York 2000 strain used in these studies, a mortality analysis alone after IC inoculation may not be sensitive enough to detect differences in CNS infection and spread. To address this, the viral burden was measured in the CNS and peripheral tissues of wild-type, RL–/–, and PKR–/– x RL–/– mice on days 2, 4, and 6 after IC inoculation. Interestingly, the average viral burden in the brains of PKR–/– x RL–/– mice was 10-fold higher than in wild-type mice on day 6 (108.2 PFU/g versus 107.0 PFU/g) (Fig. 4B). As anticipated because of the requirement for time-dependent spread, infectious virus was not detected in the spinal cord on day 2 after IC infection in any group. By day 4, 50% (four of eight) of the wild-type mice had measurable loads of virus in their spinal cords, with an average of 103.7 PFU/g. At this time point, 100% (eight of eight) of both the RL–/– and the PKR–/– x RL–/– mice had infectious virus in their spinal cords, with higher viral burdens (10 4.7 PFU/g and 105.5 PFU/g, respectively, compared to 103.7 PFU/g in wild-type mice; P < 0.04) (Fig. 4C). At day 6, increased viral loads in the spinal cord again were detected in mice lacking both PKR and RNase L. These data suggest that PKR and RNase L contribute to the control of WNV replication in CNS tissues directly.

Although intracranial infection of WNV results in rapid, overwhelming replication in the brain and spinal cord, viral spread to peripheral tissues also can occur. Since PKR and RNase L restricted viral infection in specific cell populations in the spleen, we evaluated whether these effector proteins modulated WNV spread following IC infection. Fifty percent of wild-type mice (two of four) had infectious virus in the spleen beginning on day 4 after infection; WNV was completely cleared by day 6, despite increasing CNS titers. In comparison, all RL–/– (four of four) and PKR–/– x RL–/– mice (eight of eight) had infectious virus in their spleens on day 4, with significantly higher viral loads than those in wild-type mice (106.5 PFU/g and 106.6 PFU/g, respectively, versus 105.7 PFU/g in wild-type mice; P ≤ 0.03) (Fig. 4D). Additionally, an attenuated clearance from the spleen was observed in RL–/– and PKR–/– x RL–/– mice, with detectable virus at day 6 postinfection in 75% (6 of 8) and 64% (7 of 11) of spleens of RL–/– and PKR–/– x RL–/– mice, respectively. Although the spleen is a normal target for WNV infection in multiple infection models (14, 53, 66), WNV replication is not consistently detected in other peripheral nonlymphoid organs. However, mice lacking the type I IFN receptor showed an expanded WNV tropism in peripheral tissues (62). To assess whether a lack of PKR and RNase L also modulated WNV tropism, viral burden in the liver was evaluated after IC infection. Consistent with our findings after subcutaneous infection (14), infectious WNV was not detected in the livers of wild-type mice at any time point. However, PKR–/– x RL–/– mice developed hepatic infection beginning on day 4 (Fig. 4E), and by day 6 after infection, 90% (9 of 10) of PKR–/– x RL–/– mice and 25% (2 of 8) RL–/– mice had measurable levels of virus in their livers, with an average of 103.6 PFU/g. Thus, deficiencies in PKR and RNase L resulted in an altered viral tropism at a tissue level.

PKR and RNase L act as IFN-activated antiviral effector proteins in cortical neurons. Although in vivo studies suggested that PKR and RNase L modulate viral replication in CNS tissues (Fig. 4), their direct role in inhibiting viral infection in neurons remained unclear. To assess whether PKR and RNase L mediated the antiviral effects of IFN in CNS-derived neurons, we infected wild-type and congenic RL–/– and PKR–/– x RL–/– primary cortical neurons in the presence or absence of IFN pretreatment. Cortical neurons were used because this neuronal subtype is infected in human and animal cases of WNV encephalitis (14, 55, 76). Pretreatment with IFN-{alpha}, -ß, or -{gamma} reduced WNV infection 8- to 15-fold in wild-type cortical neurons. A decrease in IFN-{alpha}- and IFN-ß-mediated inhibition of WNV infection was observed in PKR–/– x RL–/– neurons (two- and threefold reduction, respectively; P ≤ 0.02) (Fig. 5A). To test whether the antiviral roles of PKR and RNase L varied among neuronal subtypes, SCG peripheral nervous system sympathetic motor neurons were generated from wild-type and congenic RL–/– and PKR–/– x RL–/– mice and infected with WNV with and without IFN pretreatment. In contrast to cortical neurons, SCG neurons lacking PKR and RNase L showed no significant decrease in the inhibition of WNV following treatment with IFN-{alpha} or IFN-ß (P ≥ 0.2) (Fig. 5B). Thus, while PKR and RNase L contribute to the antiviral effects of type I IFN in cortical neurons, independent effector molecules may play dominant antiviral roles in other neuronal subtypes. To confirm that the PKR activation pathway was functional in cortical neurons and begin to evaluate other downstream targets of type I IFN in this cell type, we performed Western blot analyses of cortical neuron lysates generated from WNV-infected and IFN-ß-treated cells (Fig. 5C). PKR was detectable at 12 h after IFN treatment and throughout the infection time course. Importantly, PKR phosphorylation was associated with a reduction in the steady-state levels of viral protein, and phosphorylated PKR and phosphorylated eIF2-{alpha} were detected 24 h sooner than ISG54 and ISG56 after WNV infection. Consistent with our virologic results, these data demonstrate that PKR is activated in cortical neurons in response to WNV infection.


Figure 5
View larger version (40K):
[in this window]
[in a new window]
  		FIG. 5. Effects of PKR and RNase L on IFN-mediated inhibition of WNV infection in neurons. (A and B) Primary cultures of cortical and SCG neurons were prepared from wild-type, RL–/–, and PKR–/–RL–/– mice. Cortical neurons (A) or SCG neurons (B) were treated 24 h prior to infection with 100 IU/ml of the indicated mouse IFN. Neurons were infected with WNV and evaluated for the production of infectious virus at 24 h by a plaque assay. Data represent averages of results from three to five independent experiments, and asterisks indicate values that are statistically significant (P < 0.05) compared to those for treated wild-type cells. (C) Whole-cell lysates were generated at the indicated times (hours postinfection [hpi]) from cortical neurons that were uninfected (lanes U), infected with WNV at an MOI of 0.1 (lanes W), treated with IFN-ß at 100 IU/ml (lanes I), or infected with WNV and treated with IFN at the time of infection (lanes I/W). Protein levels of phosphorylated PKR (PKR-P), phosphorylated eIF2-{alpha} (eIF2{alpha}-P), total PKR, total eIF2-{alpha}, mouse IRF-3, ISG56, ISG54, WNV, and GAPDH were examined by immunoblot analysis.

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we used several different experimental approaches to demonstrate that PKR and RNase L act as important effector molecules against WNV infection. Mice lacking PKR and RNase L were significantly more susceptible to WNV infection and showed increased viremia and viral burden in peripheral tissues, early entry into the brain, and higher viral loads in the CNS than wild-type mice. In vivo and in vitro studies suggest that CD11b+ bone marrow-derived cells specifically utilize PKR and RNase L to modulate WNV replication. PKR- and RNase L-deficient mice also showed higher viral burdens in CNS tissues following IC inoculation. Experiments in primary cortical neurons suggest that PKR and RNase L contribute to IFN-mediated protection against WNV, as genetically deficient neurons showed reduced sensitivity to the antiviral effects of type I IFN.

PKR and RNase L modulate WNV pathogenesis in mice. Although in vivo and in vitro studies have demonstrated that type I IFN limits WNV infection and spread (62), the IFN-induced antiviral molecules that control WNV infection remain unidentified. Our experiments show that PKR and RNase L contribute to the control of WNV replication in vivo, as increased lethality following peripheral inoculation was observed in RL–/– and PKR–/– x RL–/– mice. Nonetheless, RNase L-deficient mice were less susceptible than mice lacking both effector proteins, suggesting an additional protective role for PKR. PKR and RNase L together contribute to the control of WNV infection in the periphery, as enhanced viral burdens were observed in lymphoid tissues and sera of mice lacking both effectors. This increase in peripheral infection correlated with an earlier entry into the brain and higher CNS viral burdens. The change in peripheral replication and dissemination did not appear to be due to a defect in immune priming, as normal levels of type I IFN and WNV-specific IgM were induced. However, because type I IFN-{alpha}/ß receptor-deficient mice showed a more severe phenotype than PKR–/– x RL–/– mice, additional, as-yet-undefined, IFN-activated effector molecules must also control WNV infection.

Though studies to date have not directly tested the role of PKR and RNase L in modulating flavivirus infection in vivo, components of the RNase L signaling pathway have been implicated in the control of WNV infection. WNV replicated to higher titers in RNase L-deficient MEFs, though this increase appeared to be independent of type I IFN (64). Additionally, a mutation in the 2',5'-oligoadenylate synthetase 1b (Oas1b) gene that results in the expression of truncated Oas1b was correlated with WNV susceptibility in mice (51, 56). The overexpression of full-length but not truncated Oas1b in MEFs decreased WNV replication by reducing the accumulation of positive-strand RNA (34), and some single-nucleotide polymorphisms in OAS genes were found at a higher frequency in humans hospitalized for WNV infection (77). However, the mechanisms by which Oas1b alleles affect WNV pathogenesis remain unclear. Recent studies suggest that RNase L activation does not play a significant role in Oas1b-dependent resistance to flaviviruses. Levels of RNase L activation were comparable in cells derived from mice that expressed full-length and truncated Oas1b genes. Furthermore, RNase L inhibition or genetic deficiency resulted in similar increases in WNV replication in both Oas1b-sufficient and -deficient backgrounds (64). Our data support an Oas1b-independent mechanism for RNase L-mediated protection from WNV infection in vivo: the RL–/– and PKR–/– x RL–/– C57BL/6 mice used in this study express the truncated form of the Oas1b gene.

The experiments described here are consistent with prior in vivo investigations of other DNA and RNA viruses. RNase L-deficient mice had increased lethality following encephalomyocarditis virus infection in both the presence and absence of IFN-{alpha} pretreatment (81). Similarly, mice lacking PKR or RNase L had significantly increased lethality following infection with coxsackievirus (20), and PKR–/– mice also showed increased lethality following VSV infection (16, 71). In contrast, PKR–/– x RL–/– mice showed no increase in morbidity or mortality following subcutaneous infection with Sindbis alphavirus, although higher viral loads were observed in draining lymph nodes (60). While the contribution of PKR and RNase L to IFN-induced protection appears to vary among viral families, our data suggest that these effector proteins can significantly modulate the severity and outcome of WNV infection.

PKR and RNase L have cell-restricted roles in modulating WNV infection. Previous experiments demonstrated that type I IFN limits WNV replication in several cell populations in vivo and in vitro, with bone marrow-derived cells and neurons showing markedly altered infection patterns in the absence of IFN-mediated protection (62). Our current study begins to elucidate which antiviral effector proteins downstream of IFN affect WNV infection. We observed increased levels of infectious WNV in type I IFN-{alpha}/ß receptor-deficient mice that were similar to those observed in both the spleens and livers of PKR–/– x RL–/– mice. Higher levels of positive-strand RNA were detected in CD11b+, CD11c+, and CD19+ cells derived from the spleens of PKR–/– x RL–/– and RL–/– mice. Negative-strand viral RNA, the replicative intermediate of WNV, however, was measurable only in CD11b+ cells from PKR–/– x RL–/– mice. Our in vitro data supported the hypothesis that PKR and RNase L restrict WNV replication in CD11b+ cells: type I IFN-mediated inhibition of WNV was partially dependent on PKR and RNase L in BM-M{phi}s, and this phenotype was associated with increased replication in BM-M{phi}s lacking both effector molecules. In contrast, responsiveness to type I IFN appeared intact in PKR- and RNase L-deficient BM-DCs. We did observe a slight decrease in the ability of PKR–/– x RL–/– BM-DCs to inhibit WNV in response to IFN-{gamma}, although this phenotype was not associated with increased WNV replication in a multistep growth curve analysis. These data suggest that type I IFN limits WNV replication in CD11b+ cells in the spleen in part through the antiviral activities of PKR and RNase L but that additional IFN-simulated genes likely play dominant inhibitory roles in other spleen cell populations.

In addition to conferring protection to bone marrow-derived cells, our experiments suggest that PKR and RNase L mediate the antiviral effects of IFN directly in the CNS. Although mice lacking PKR and RNase L did not show enhanced lethality after IC infection, higher CNS viral burdens were observed. Consistent with this, PKR and RNase L partially mediated the antiviral effects of type I IFN in cortical neurons. The PKR pathway was rapidly activated in cortical neurons by WNV infection, and this occurred 24 h prior to the induction of other ISGs. We speculate that PKR may restrict WNV replication in cortical neurons prior to the production of other antiviral proteins, an idea consistent with the ability of PKR to mediate eIF2-{alpha}-dependent translational shutoff (35, 61, 74). In contrast, PKR and RNase L did not appear to mediate the antiviral effects of type I IFN in SCG sympathetic motor neurons of peripheral origin.

Our studies suggest that PKR and RNase L mediate the IFN inhibition of WNV in some cell populations but are dispensable for the control of infection in others. Analogously, different cell types have shown varied requirements for PKR and RNase L in the context of other viral infections. Although the interferon responsiveness of PKR–/– x RL–/– MEFs or BM-DCs was largely intact in the context of DENV or WNV infection (13, 64), MEFs deficient in PKR showed a decreased IFN-mediated inhibition of VSV (71). Moreover, our results agree with prior reports that showed that PKR and RNase L were important for IFN-ß-mediated resistance to HSV type 1 in trigeminal ganglion cultures (2) but that PKR was dispensable for the IFN-{gamma}-mediated inhibition of vesicular stomatitis virus in neuroblastoma cells (12). We postulate a model in which distinct cell types differentially utilize PKR and RNase L to inhibit viral infection. This variable requirement for PKR and RNase L suggests that cell-specific antiviral programs that may differ in both the kinetics and repertoire of IFN-induced antiviral proteins are induced by IFN. To this end, genetic profiling studies are under way to identify novel cell-specific IFN-induced antiviral pathways that inhibit WNV.


   ACKNOWLEDGMENTS
 
We thank R. Klein, M. Colonna, and members of their laboratories for experiment advice.

This work was supported by a New Scholar Award in Global Infectious Disease from the Ellison Medical Foundation (M.S.D.), a predoctoral fellowship from the Howard Hughes Medical Institute (M.A.S.), and NIH grants CA44059 (R.H.S.), A134039 (B.R.G.W.), and AI057568 (M.G.).


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, Campus Box 8051, 660 S. Euclid Ave., St. Louis, MO 63110. Phone: (314) 362-2842. Fax: (314) 362-9230. E-mail address: diamond{at}borcim.wustl.edu. Back

{dagger} Present address: Discovery Biology, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, United Kingdom. Back

{ddagger} Present address: Monash Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton, Victoria 3168, Australia Back


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738.[CrossRef][Medline]
  2. Al-khatib, K., B. R. Williams, R. H. Silverman, W. Halford, and D. J. Carr. 2003. The murine double-stranded RNA-dependent protein kinase PKR and the murine 2',5'-oligoadenylate synthetase-dependent RNase L are required for IFN-beta-mediated resistance against herpes simplex virus type 1 in primary trigeminal ganglion culture. Virology 313:126-135.[CrossRef][Medline]
  3. Asnis, D. S., R. Conetta, A. A. Teixeira, G. Waldman, and B. A. Sampson. 2000. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin. Infect. Dis. 30:413-418.[CrossRef][Medline]
  4. Austin, B. A., C. James, R. H. Silverman, and D. J. Carr. 2005. Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J. Immunol. 175:1100-1106.[Abstract/Free Full Text]
  5. Balachandran, S., P. C. Roberts, L. E. Brown, H. Truong, A. K. Pattnaik, D. R. Archer, and G. N. Barber. 2000. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13:129-141.[CrossRef][Medline]
  6. Byrne, S. N., G. M. Halliday, L. J. Johnston, and N. J. King. 2001. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J. Investig. Dermatol. 117:702-709.[CrossRef][Medline]
  7. Carr, D. J., K. Al-khatib, C. M. James, and R. Silverman. 2003. Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway. J. Neuroimmunol. 141:40-46.[CrossRef][Medline]
  8. Ceausu, E., S. Erscoiu, P. Calistru, D. Ispas, O. Dorobat, M. Homos, C. Barbulescu, I. Cojocaru, C. V. Simion, C. Cristea, C. Oprea, C. Dumitrescu, D. Duiculescu, I. Marcu, C. Mociornita, T. Stoicev, I. Zolotusca, C. Calomfirescu, R. Rusu, R. Hodrea, S. Geamai, and L. Paun. 1997. Clinical manifestations in the West Nile virus outbreak. Rom. J. Virol. 48:3-11.[Medline]
  9. Celada, A., P. W. Gray, E. Rinderknecht, and R. D. Schreiber. 1984. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J. Exp. Med. 160:55-74.[Abstract/Free Full Text]
  10. Ceppi, M., N. Ruggli, V. Tache, H. Gerber, K. C. McCullough, and A. Summerfield. 2005. Double-stranded secondary structures on mRNA induce type I interferon (IFN alpha/beta) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J. Gene Med. 7:452-465.[CrossRef][Medline]
  11. Chambers, T. J., and M. S. Diamond. 2003. Pathogenesis of flavivirus encephalitis. Adv. Virus Res. 60:273-342.[CrossRef][Medline]
  12. Chesler, D. A., J. L. Munoz-Jordan, N. Donelan, A. Garcia-Sastre, and C. S. Reiss. 2003. PKR is not required for interferon-gamma inhibition of VSV replication in neurons. Viral Immunol. 16:87-96.[CrossRef][Medline]
  13. Diamond, M. S., and E. Harris. 2001. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289:297-311.[CrossRef][Medline]
  14. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.[Abstract/Free Full Text]
  15. Diamond, M. S., E. M. Sitati, L. D. Friend, S. Higgs, B. Shrestha, and M. Engle. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.[Abstract/Free Full Text]
  16. Durbin, R. K., S. E. Mertz, A. E. Koromilas, and J. E. Durbin. 2002. PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol. 15:41-51.[CrossRef][Medline]
  17. Easton, R. M., T. L. Deckwerth, A. S. Parsadanian, and E. M. Johnson, Jr. 1997. Analysis of the mechanism of loss of trophic factor dependence associated with neuronal maturation: a phenotype indistinguishable from Bax deletion. J. Neurosci. 17:9656-9666.[Abstract/Free Full Text]
  18. Ebel, G. D., A. P. Dupuis III, K. Ngo, D. Nicholas, E. Kauffman, S. A. Jones, D. Young, J. Maffei, P. Y. Shi, K. Bernard, and L. D. Kramer. 2001. Partial genetic characterization of West Nile virus strains, New York State, 2000. Emerg. Infect. Dis. 7:650-653.[Medline]
  19. Eldadah, A. H., and N. Nathanson. 1967. Pathogenesis of West Nile Virus encephalitis in mice and rats. II. Virus multiplication, evolution of immunofluorescence, and development of histological lesions in the brain. Am. J. Epidemiol. 86:776-790.[Free Full Text]
  20. Flodstrom-Tullberg, M., M. Hultcrantz, A. Stotland, A. Maday, D. Tsai, C. Fine, B. Williams, R. Silverman, and N. Sarvetnick. 2005. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J. Immunol. 174:1171-1177.[Abstract/Free Full Text]
  21. Fratkin, J. D., A. A. Leis, D. S. Stokic, S. A. Slavinski, and R. W. Geiss. 2004. Spinal cord neuropathology in human West Nile virus infection. Arch. Pathol. Lab. Med. 128:533-537.[Medline]
  22. Fredericksen, B. L., and M. Gale, Jr. 2006. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J. Virol. 80:2913-2923.[Abstract/Free Full Text]
  23. Fredericksen, B. L., M. Smith, M. G. Katze, P. Y. Shi, and M. Gale, Jr. 2004. The host response to West Nile virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78:7737-7747.[Abstract/Free Full Text]
  24. Gale, M., Jr., B. Kwieciszewski, M. Dossett, H. Nakao, and M. G. Katze. 1999. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J. Virol. 73:6506-6516.[Abstract/Free Full Text]
  25. Glass, W. G., J. K. Lim, R. Cholera, A. G. Pletnev, J. L. Gao, and P. M. Murphy. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202:1087-1098.[Abstract/Free Full Text]
  26. Glass, W. G., D. H. McDermott, J. K. Lim, S. Lekhong, S. F. Yu, W. A. Frank, J. Pape, R. C. Cheshier, and P. M. Murphy. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203:35-40.[Abstract/Free Full Text]
  27. Gomez, C. E., A. M. Vandermeeren, M. A. Garcia, E. Domingo-Gil, and M. Esteban. 2005. Involvement of PKR and RNase L in translational control and induction of apoptosis after hepatitis C polyprotein expression from a vaccinia virus recombinant. Virol. J. 2:81.[CrossRef][Medline]
  28. Gorchakov, R., E. Frolova, B. R. G. Williams, C. M. Rice, and I. Frolov. 2004. PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J. Virol. 78:8455-8467.[Abstract/Free Full Text]
  29. Granwehr, B. P., K. M. Lillibridge, S. Higgs, P. W. Mason, J. F. Aronson, G. A. Campbell, and A. D. Barrett. 2004. West Nile virus: where are we now? Lancet Infect. Dis. 4:547-556.[CrossRef][Medline]
  30. Guo, J. T., J. Hayashi, and C. Seeger. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79:1343-1350.[Abstract/Free Full Text]
  31. Hornung, V., J. Schlender, M. Guenthner-Biller, S. Rothenfusser, S. Endres, K. K. Conzelmann, and G. Hartmann. 2004. Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J. Immunol. 173:5935-5943.[Abstract/Free Full Text]
  32. Huhn, G. D., C. Austin, C. Langkop, K. Kelly, R. Lucht, R. Lampman, R. Novak, L. Haramis, R. Boker, S. Smith, M. Chudoba, S. Gerber, C. Conover, and M. S. Dworkin. 2005. The emergence of West Nile virus during a large outbreak in Illinois in 2002. Am. J. Trop. Med. Hyg. 72:768-776.[Abstract/Free Full Text]
  33. Johnston, L. J., G. M. Halliday, and N. J. King. 2000. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Investig. Dermatol. 114:560-568.[CrossRef][Medline]
  34. Kajaste-Rudnitski, A., T. Mashimo, M. P. Frenkiel, J. L. Guenet, M. Lucas, and P. Despres. 2006. The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J. Biol. Chem. 281:4624-4637.[Abstract/Free Full Text]
  35. Katze, M. G. 1995. Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol. 3:75-78.[CrossRef][Medline]
  36. Kerr, I. M., and R. E. Brown. 1978. pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl. Acad. Sci. USA 75:256-260.[Abstract/Free Full Text]
  37. Khabar, K. S., M. Dhalla, Y. Siddiqui, A. Zhou, M. N. Al-Ahdal, S. D. Der, R. H. Silverman, and B. R. Williams. 2000. Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. J. Interferon Cytokine Res. 20:653-659.[CrossRef][Medline]
  38. Klein, R. S., E. Lin, B. Zhang, A. D. Luster, J. Tollett, M. A. Samuel, M. Engle, and M. S. Diamond. 2005. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79:11457-11466.[Abstract/Free Full Text]
  39. Kleinschmidt-DeMasters, B. K., B. A. Marder, M. E. Levi, S. P. Laird, J. T. McNutt, E. J. Escott, G. T. Everson, and K. L. Tyler. 2004. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch. Neurol. 61:1210-1220.[Abstract/Free Full Text]
  40. Koromilas, A. E., C. Cantin, A. W. Craig, R. Jagus, J. Hiscott, and N. Sonenberg. 1995. The interferon-inducible protein kinase PKR modulates the transcriptional activation of immunoglobulin kappa gene. J. Biol. Chem. 270:25426-25434.[Abstract/Free Full Text]
  41. Kumar, A., J. Haque, J. Lacoste, J. Hiscott, and B. R. Williams. 1994. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc. Natl. Acad. Sci. USA 91:6288-6292.[Abstract/Free Full Text]
  42. Lanciotti, R. S., A. J. Kerst, R. S. Nasci, M. S. Godsey, C. J. Mitchell, H. M. Savage, N. Komar, N. A. Panella, B. C. Allen, K. E. Volpe, B. S. Davis, and J. T. Roehrig. 2000. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J. Clin. Microbiol. 38:4066-4071.[Abstract/Free Full Text]
  43. Leis, A. A., J. Fratkin, D. S. Stokic, T. Harrington, R. M. Webb, and S. A. Slavinski. 2003. West Nile poliomyelitis. Lancet Infect. Dis. 3:9-10.[CrossRef][Medline]
  44. Leis, A. A., D. S. Stokic, J. L. Polk, V. Dostrow, and M. Winkelmann. 2002. A poliomyelitis-like syndrome from West Nile virus infection. N. Engl. J. Med. 347:1279-1280.[Free Full Text]
  45. Li, X.-L., J. A. Blackford, and B. A. Hassel. 1998. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J. Virol. 72:2752-2759.[Abstract/Free Full Text]
  46. Lin, R.-J., C.-L. Liao, E. Lin, and Y.-L. Lin. 2004. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J. Virol. 78:9285-9294.[Abstract/Free Full Text]
  47. Liu, W. J., X. J. Wang, D. C. Clark, M. Lobigs, R. A. Hall, and A. A. Khromykh. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80:2396-2404.[Abstract/Free Full Text]
  48. Liu, W. J., X. J. Wang, V. V. Mokhonov, P.-Y. Shi, R. Randall, and A. A. Khromykh. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79:1934-1942.[Abstract/Free Full Text]
  49. Lobigs, M., A. Mullbacher, Y. Wang, M. Pavy, and E. Lee. 2003. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J. Gen. Virol. 84:567-572.[Abstract/Free Full Text]
  50. Malmgaard, L., J. Melchjorsen, A. G. Bowie, S. C. Mogensen, and S. R. Paludan. 2004. Viral activation of macrophages through TLR-dependent and -independent pathways. J. Immunol. 173:6890-6898.[Abstract/Free Full Text]
  51. Mashimo, T., M. Lucas, D. Simon-Chazottes, M. P. Frenkiel, X. Montagutelli, P. E. Ceccaldi, V. Deubel, J. L. Guenet, and P. Despres. 2002. A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. USA 99:11311-11316.[Abstract/Free Full Text]
  52. Meurs, E. F., Y. Watanabe, S. Kadereit, G. N. Barber, M. G. Katze, K. Chong, B. R. G. Williams, and A. G. Hovanessian. 1992. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66:5805-5814.[Abstract/Free Full Text]
  53. Morrey, J. D., C. W. Day, J. G. Julander, A. L. Olsen, R. W. Sidwell, C. D. Cheney, and L. M. Blatt. 2004. Modeling hamsters for evaluating West Nile virus therapies. Antivir. Res. 63:41-50.[CrossRef][Medline]
  54. Munoz-Jordan, J. L., G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 100:14333-14338.[Abstract/Free Full Text]
  55. Omalu, B. I., A. A. Shakir, G. Wang, W. I.